Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.

There has been considerable debate whether established cutaneous psoriasis patients can avert or lessen the risk of future inflammatory arthritis if treated aggressively with biologic therapy.